NCT02516241 2026-04-20
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
Phase 3 Active not recruiting
AstraZeneca
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Bristol-Myers Squibb
Hoffmann-La Roche